Category: How To Grow Orchids

Pharma Contract Manufacturing: World Market Outlook 2013-2023

London (PRWEB) November 12, 2013

Report Details

Contracted drug production – discover trends and segments with highest revenue potential

Where’s outsourced pharma manufacturing heading? Visiongain’s updated report predicts that industry’s revenues from 2013. There you find potentials for sales growth, also understanding trends, technologies for drugs, clients’ needs, and opportunities.

That study gives you revenue forecasts to 2023 at overall world market, submarket, and national level. Avoid falling behind, then. Instead see what’s happening for those medical contracting services – outsourcing and off-shoring – finding how you can gain.

Read on to scan that industry and see what its future market could be worth.

Forecasts from 2013-2023 and other analyses show you the commercial prospects

Besides revenue forecasting to 2023, our new study shows you historical data, growth rates, and market shares. Hear, too, about developments in technology and service offerings. You also get 82 tables, 61 charts, and three interviews with leaders in companies.

Gains through understanding those outsourcing services – advantages for your work.

Data searches can be hard work – all that looking. But now you can stay ahead in knowledge for contracted drug making, benefiting your research, analysis, and decisions. Finding information you need for producing medicines just got quicker and easier.

Use our predictions to help expand your business and give you more influence. You get the forecasting leaders need. So avoid falling behind, instead trying our new report now.

There you hear what’s happening in the industry for contract manufacturing organisations (CMOs). You also see where needs and money exist, to 2023, finding the potential gains.

The following sections show how you benefit from that new investigation.

Forecasts from 2013 for the world market and submarkets for outsourced drug producing

What are the secrets of that industry’s progress? Discover expected trends there. Along with prediction of the overall world market for out-contracting drug production, our report shows you revenue forecasting of 11 submarkets to 2023 at world level:

Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs), and related products

Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages, and other agents

Other applications of outsourced production – other services

Clinical manufacturing

Commercial manufacturing.

Those analyses and discussions show you commercial potentials for manufacturing service providers and their technologies. Discover those money-gaining prospects.

You find geographical revenue predictions too.

National and regional markets – what outlooks for demand, service provision, and sales?

In developed and developing countries, opportunities for pharmaceutical CMOs will occur, often with rising potential. You see where and how.

Our analyses give individual revenue forecasts to 2023 for 12 national markets:

United States (US)

Japan

EU leaders – Germany, France, the UK, Italy, and Spain (EU5), with an EU forecast

BRIC countries – Brazil, Russia, India, and China

South Korea.

There you hear about progress and outlooks. You find opportunity. Assess that medical production sector’s future – hear about developments and find their significance.

See there what’s likely to happen. Our work explains, exploring issues.

Developments, challenges, and opportunities affecting CMOs and clients

The report shows you activities and events affecting that industry and market from 2013, including these:

Trends for investing in biopharma manufacturing

Demands for formulation developing services

Potential for microreactors in drug making

EU regulations and API production

Backwards integration for generics manufacturers

US generic drug user fee act and API producing.

Our analysis discusses other aspects of the technologies and services too, including these:

Investment in HPAPI manufacturing facilities

Demand for softgel formulations and the shift to continuous manufacturing

Complex-molecule production, esp. biologics (inc. biosimilars) and orphan drugs

Development of antibody-drug conjugates (ADCs)

Lyophilisation, other drying technology, and aseptic filling

Technologies to stimulate market expansion.

There you explore political, economic, social, and technological questions, assessing outlooks for business. Examine what forces stimulate and what restrain that industry.

You also see regulatory developments. You discover, then, what that industry’s present and future hold, exploring issues for clients and service providers.

Companies and overall 2017 market value – how high can revenues go?

What’s possible for that industry? Our analysis predicts the world market for contract pharma manufacturing will reach $ 69.7bn in 2017. It will rise from $ 51.7bn in 2012, with growth to 2023.

Our study explains what service needs, pharma technologies, and outsourcing providers hold greatest commercial potential.

In particular, you explore activities of these companies:

Catalent Pharma Solutions

Lonza

Evonik Degussa

Royal DSM

Teva API.

You also find discussions of these firms, among other players:

Patheon

Boehringer BioXcellence

Famar

Fareva

Vetter Pharma.

There you analyse participants’ financial results, market shares, activities, and outlooks. You find 150 organisations mentioned. You also read three interviews with companies.

Discover what authorities there do, say, and think, helping you stay ahead.

Research and analysis on the CMO industry and market – data found nowhere else

In particular, then, our new investigation gives you these advantages:

Revenues to 2023 for outsourced medicine production at world level, with forecasting of 11 submarkets – explore prospects for sales and investments

Forecasts to 2023 for 12 national markets in the Americas, Europe, and Asia – investigate developed and developing countries for revenue potentials

Outlooks for established and rising CMOs – assess market shares, portfolios, results, capabilities, clients, and prospects.

Pharma Contract Manufacturing: World Market Outlook 2013-2023 provides independent analysis. There you receive business intelligence found only in our work, finding where money lies.

Gain recognition, too, for insight. With that report you’re less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analysis, and decisions, also saving time.

1. Executive Summary

1.1 Pharma Contract Manufacturing: World Market Overview 2013

1.2 Report Contents

1.3 Research and Analysis Methods

1.4 An Introduction to Pharma Contract Manufacturing

1.4.1 Why Outsource in the Pharma Industry?

1.4.2 Services Offered by CMOs

1.4.3 Tactical and Strategic Manufacturing Outsourcing

1.4.4 Trends in Contract Manufacturing 2013-2023

2. The Pharma Contract Manufacturing Market: Outlook and Forecast 2013-2023

2.1 The Pharma Contract Manufacturing: Market Performance 2010-2012

2.1.1 Contract Manufacturing Is the Most Mature Pharma Outsourcing Sector

2.1.2 The Pharma Contract Manufacturing Mar

More How To Grow Orchids Press Releases

Groom viburnum to pilfer pungency

Groom viburnum to pilfer pungency
A: Some orchids never see traditional containers but hang with bare roots in baskets. These normally need extra attention to waterings and feedings so most are grown in barks or a similar medium. When orchids overflow containers with roots or the …
Read more on Orlando Sentinel

GMO ban, research at odds?
Michael Shintaku, a plant pathologist at the University of Hawaii at Hilo, said he is continuing his research on creating lettuce resistant to the tomato spotted wilt virus but is unsure of whether he can get it approved with the current restrictions …
Read more on West Hawaii Today

How I made a garden for all seasons
I am a nester: someone who lays down deep roots and puts their heart and soul into gardening and homemaking. Little did I think I'd ever move from our home of 30 years but, when your family grows up and moves away, when career paths change and …
Read more on Telegraph.co.uk

BAASS Business Solutions Inc. Celebrates a Successful BAASS Connect 2013 Conference in Edmonton


Edmonton, Alberta (PRWEB) November 01, 2013

BAASS Business Solutions Inc. (BAASS), a distinguished North American Sage ERP partner, celebrated the success of its 16th annual conference called BAASS Connect (formerly Accpac Live) on October 24th, 2013 in Edmonton.

After operating under the Accpac Live name for 15 years, BAASS has rebranded the conference as BAASS Connect to reflect the need to create a more connected business environment. The rebrand highlights the opportunity attendees had to connect with fellow software users, product experts, support analysts, and product leadersall under one roof. The new conference location, the Holiday Inn Conference Centre in Edmonton, served as the ideal setting for establishing new and lasting business relationships benefiting all parties.

The conference featured speakers who engaged attendees on a variety of topics including Human Resource Management Systems (HRMS) and Customer Relationship Management (CRM). The professional team at BAASS showcased how businesses can manage their internal relationships using HRMS while managing their external relationships using CRM.

This years award winners included Manus Abrasive Systems in the category of Growing with Sage and Merit Contractors Association in the category of CRM Excellence. Manus Abrasive Systems, Canadas largest supplier of abrasive blast equipment with over 20 active ERP users, streamlined their sales and marketing processes with Sage CRM, which they fully integrated with AutoSimply Manufacturing and Orchids Process Scheduling. Merit Contractors Association, a provider of Health and Safety training related courses for the Construction industry, was awarded the CRM Excellence award for fully adopting Sage CRM across the organization and utilizing it as the hub of their business. By integrating Sage CRM with their online ecommerce platform and Sage 300 ERP software, Merit has adopted CRM as a comprehensive business strategy.

Throughout the past year, weve had the opportunity to meet and engage with a number of prestigious companies and customers,” said Joseph Arnone, President of BAASS. “Were extending this token of appreciation to commemorate outstanding achievement and creativity in the use of software as a tool toward greater efficiency and effectiveness in the use of available resources.

During the conference, more third party exhibitors were given a chance to showcase their solutions. This years conference exhibitors included BI Metrix, Iciniti, Industrios Software Inc., Manusonic, North 49, Rob Lavery & Associates, and XM Developments.

The Edmonton Conference marks the first of four conferences spanning the country. Please join us next in London, Burlington, and Toronto, Ontario on November 12th, 13th, and 14th respectively to partake in the largest Sage partner Conference in North America. Stay connected by following us on Twitter for the latest updates on #BAASSConnect_2013.

###

About BAASS Business Solutions Inc.

Established in 1988 and this year celebrating its 25th year in business, BAASS has been successfully assisting small and medium sized businesses improve their business processes, increase productivity and efficiency, and become more profitable. Our dedicated team of professionals have earned a reputation for their expertise, professionalism, and integrity serving clients throughout North America, Latin America, and the Caribbean. BAASS has been recognized within the industry on numerous occasions for excellence in customer service and has earned top 1% position in net promoter score. However the real proof is what our many satisfied clients have to say about us. As a full-service technology consulting firm, we can offer, implement, and support end-to-end solutions that work for our clients now, and in the long term. Our comprehensive range of services includes needs assessment, management consulting, system design and configuration, software training, and technical support in accounting, ERP, CRM, HRIS, e-business, business intelligence, and custom solutions.







Long Beach garden filled with botanical jewels

Long Beach garden filled with botanical jewels
"You don't see them anymore, but this is perfect for the orchids. This end is shady, so they get indirect sunlight. They love it out here. Orchids are easy to grow if you leave them alone and don't try to over-pamper them. Just let them dry out a bit …
Read more on SunHerald.com

IT'S A CORKER: Handmade tree will highlight orchids
New bark grows back on the donor tree after what's being sold is stripped off, becoming flooring, those little plugs that keep your wine from spilling out of your bottle and, of course, fake trees from which to display orchids. Having been pitched the …
Read more on Muncie Star Press

Gardens: natural born killers – carnivorous plants
In a corridor at RHS Wisley, away from the cascades of orchids belonging to the Orchid Society spring show, members of the Carnivorous Plant Society watch over tables of monstrously diverse life forms known as CP. Here, the Liberty print of the orchid …
Read more on The Guardian

Orchid care, Masdevallia Purple Orchid How to grow orchids outdoors

Orchid care, Masdevllia Raymondo Delos Andes “Lavender Ripple” Orchid is a Uniflora x macrura” Orchid require cool, humid conditions. Morning and late evenin…

This is an Oncidium Orchid display in my hallway right now, it changes all of the time depending what is in bloom. I really should fix up the pots better and…

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2013-2023

London (PRWEB) September 24, 2013

Report Details

Generics companies – assess products, developments, and revenue prospects

What does the future hold for makers of generic drugs? Visiongain’s updated report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions.

Our study analyses 50 leading generics producers and marketers. There you find information on established and rising companies. Discover their sales potentials.

Forecasts and other data to help you stay ahead

In our new study you find analytical profiles of top companies worldwide. There you analyse historical data, market shares, revenue forecasts, and growth rates. Discover qualitative analysis too. You also gain 63 charts and 96 tables.

Our work lets you assess the most lucrative parts of the world industry for generic drugs. See now how you can benefit your research, analyses, and decisions there, also saving time.

The following sections highlight what you find in our new investigation.

Assessments of top companies – activities, results, competition, and potential sales

Our report analyses 50 manufacturers of generic medicines. In general a company profile gives you the following information:

Discussion of a company’s activities, outlook, and recent financial results

Assessment of its developments – mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures

Forecasting of generic drug revenues to 2023 (for 20 of the companies).

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Now see companies you investigate there, grouped by type and geographical region.

Big pharma – generics production by the pharma industry’s largest companies

First, our study gives you discussions, financial analyses, and commercial outlooks for five generic drug producers among the world’s leading pharmaceutical companies:

Teva Pharmaceutical Industries

Novartis (Sandoz)

Abbott Laboratories

Pfizer

Sanofi.

You see possibilities there for raising business performance. Discover what the future holds for those companies, then, including revenue predictions to 2023.

North America – outlooks for leading generic drug manufacturers

Next, our report analyses 12 North American generics specialists, including these:

Mylan

Actavis

Hospira

Par Pharmaceutical

Mallinckrodt

Apotex

Valeant.

There you find where sales growth can occur. Many opportunities remain, with high, expanding revenues possible from 2013. See where best potentials exist.

Europe – prospects for leading generics players

You also discover outlooks for 11 European generics specialists, including these:

Fresenius Kabi

Pharmstandard

Stada Arzneimittel

Gedeon Richter

Krka.

Our report shows you how companies can seize opportunities and expand their businesses.

India – analysis of leading generic drug firms

Our new work also assesses 10 Indian generic drug producers, including these:

Ranbaxy Laboratories

Cipla

Dr. Reddy’s Laboratories

Lupin

Aurobindo

Wockhardt

Sun Pharmaceutical Industries.

How much sales growth and geographical expansion can Indian pharma achieve? You find revenue data, trends, and opportunities there, seeing what the present and future hold.

Producers from the rest of the world – assess progress and prospects

You also discover outlooks for 12 generic drug makers based in other regions, including these companies:

Aspen Pharmacare

Laboratorios Roemmers

Nichi-Iko

Sawai Pharmaceuticals

Taro Pharmaceutical Industries

Adcock Ingram

Eurofarma.

Developing markets such as Japan, Brazil and China will prove important for generic drug sales from 2013 to 2023, our analyses show.

Issues affecting generic drug manufacturing and selling

In addition, our report discusses issues and events affecting that industry and market from 2013, including these:

Specialty generics – difficult-to-produce medicines with high profit margins

Super-generics – shift towards innovation, with expanding R&D budgets

Mergers and acquisitions influencing that part of healthcare

Big pharma firms targeting generics – diversification of portfolios

Expansion internationally – targeting emerging national markets

Intellectual property (IP) – regulation and opportunity

Biosimilars – opportunities for generic and originator companies.

There you explore the generic drug industry’s strengths, weaknesses, opportunities, and threats. In particular, the merger of Actavis and Watson forms a notable event. Discover now what the future holds.

Ways Pharma Leader Series: Top 50 Generic Drug Manufacturers 2013-2023 helps you

In summary, then, our new research and analysis give you the following knowledge:

Profiles of 50 leading companies – assess product ranges, strategies, and sales results, also gaining revenue forecasts to 2023 for 20 organisations

Competition and opportunities – see what affects the generics market, learning what shapes its future, esp. prospects for sustaining and developing business

Analysis of what stimulates and restrains the generic medicines industry – discover challenges and strengths, helping you compete and gain advantages

Issues affecting established competitors and firms entering the generics sector – explore needs, practices, and outlooks for future success.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our new survey you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Predictions for generic drug production and sales – gain by ordering now

Our new analysis shows you data, trends, opportunities, and outlooks for producers and sellers of generic drugs. Avoid missing out – please order our report now.

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

Table of Contents

1. Executive Summary

1.1 Overview of Findings

1.2 Chapter Breakdown

1.3 Research and Analysis Methods

2. The Top 50 Generic Drug Manufacturers: Overview, 2013

2.1 Total Value of the Top 50 Generics Companies

2.2 Regional Distribution of the Top 50 Companies

2.3 Coverage in this Report

2.3.1 Issues Involved in Assessing the Top 50 Companies

2.3.2 Obtaining Data for Private Companies

2.3.3 Variable Financial Years

2.3.4 Identifying Revenues Specifically from Generics

2.3.5 Defining Generics 1: Do Biosimilars Count?

2.3.6 Defining Generics 2: ‘Super-Generics’ and APIs

2.3.7 Defining Generics 3: Rx and OTC

3. The Top Big Pharma Generic Drug Manufacturers: Overview, 2013-2023

3.1 Companies Covered in this Chapter

3.2 Why are Big Pharma Targeting Generics?

3.2.1 Is Generics Still a Dirty Word for Big Pharma?

3.2.2 Diversification or Divorce? Big Pharma Growth Strategies

3.3 Teva Phar

Find More How To Grow Orchids Press Releases

Fielding questions

Fielding questions
Blossoming is triggered by cool temperatures, and in nature orchids often grow upside down from rotten portions of trees. The aerial roots sent out by orchid plants will turn green when misted and allowed to absorb water. Clear plastic cups work well …
Read more on In-Forum

ACTIVATE YOUR ACCOUNT
Prize-winning exhibits of cut flowers and container arrangements as well as individual plants will be displayed at the Wonderful World of Orchids, the 41st annual show and sale sponsored by the Naples Orchid Society. The show begins at 3 p.m. Friday in …
Read more on Naples Daily News

Latest How To Grow Orchids News

Longwood Gardens' massive holiday display is more than just flowers
There's plenty more, from living wreaths and blooming roses to the fruit house, where trees boast handmade ornaments by kids from a dozen schools, and a tropical rainforest scene, with a tree erupting with orchids. "A Longwood Christmas," for those who …
Read more on Lancaster Newspapers

The Gardening Guy
When the leaves die, bacteria grow and slime forms – blocking the uptake of water to the flowers. So they wilt. A few years ago I called my florist to see if she had any potted phalaenopsis orchids for sale. Surprisingly, she told me to go to a big box …
Read more on The Northfield News